-
EP3788077
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3788077
| EP3788077 - ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 10.11.2022 Database last updated on 30.10.2024 | |
| Former | Request for examination was made Status updated on 05.02.2021 | ||
| Former | The international publication has been made Status updated on 08.11.2019 | ||
| Former | unknown Status updated on 08.06.2019 | Most recent event Tooltip | 06.07.2024 | New entry: Additional fee for renewal fee: despatch of communication + time limit | Applicant(s) | For all designated states CytomX Therapeutics, Inc. 151 Oyster Point Boulevard Suite 400 South San Francisco, California 94080 / US | [2021/10] | Inventor(s) | 01 /
PAIDHUNGAT, Madan M. c/o CytomX Therapeutics, Inc. 151 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 / US | 02 /
FOX, Ellaine Anne Mariano c/o CytomX Therapeutics, Inc. 151 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 / US | 03 /
MEI, Li c/o CytomX Therapeutics, Inc. 151 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 / US | [2021/10] | Representative(s) | Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ / GB | [N/P] |
| Former [2021/10] | Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS / GB | Application number, filing date | 19727548.0 | 02.05.2019 | [2021/10] | WO2019US30472 | Priority number, date | US201862666056P | 02.05.2018 Original published format: US 201862666056 P | US201862712046P | 30.07.2018 Original published format: US 201862712046 P | [2021/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019213444 | Date: | 07.11.2019 | Language: | EN | [2019/45] | Type: | A1 Application with search report | No.: | EP3788077 | Date: | 10.03.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.11.2019 takes the place of the publication of the European patent application. | [2021/10] | Search report(s) | International search report - published on: | EP | 07.11.2019 | Classification | IPC: | C07K16/28, C07K14/705, A61P35/00 | [2021/10] | CPC: |
C07K16/2863 (EP,US);
A61K31/713 (US);
A61K39/3955 (US);
A61P35/00 (EP,US);
C07K16/2809 (EP,US);
C12N15/63 (US);
C12N5/10 (US);
A61K2039/505 (EP);
C07K2317/31 (EP,US);
C07K2317/51 (US);
C07K2317/515 (US);
C07K2317/52 (US);
C07K2317/622 (EP,US);
C07K2317/64 (EP);
C07K2317/76 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/10] | Title | German: | ANTIKÖRPER, AKTIVIERBARE ANTIKÖRPER, BISPEZIFISCHE ANTIKÖRPER UND BISPEZIFISCHE AKTIVIERBARE ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON | [2021/10] | English: | ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | [2021/10] | French: | ANTICORPS, ANTICORPS ACTIVABLES, ANTICORPS BISPÉCIFIQUES, ET ANTICORPS ACTIVABLES BISPÉCIFIQUES ET LEURS MÉTHODES D'UTILISATION | [2021/10] | Entry into regional phase | 18.11.2020 | National basic fee paid | 18.11.2020 | Designation fee(s) paid | 18.11.2020 | Examination fee paid | Examination procedure | 18.11.2020 | Examination requested [2021/10] | 18.11.2020 | Date on which the examining division has become responsible | 18.06.2021 | Amendment by applicant (claims and/or description) | 09.11.2022 | Despatch of a communication from the examining division (Time limit: M06) | 14.06.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 23.08.2023 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 23.08.2023 | Request for further processing filed | 23.08.2023 | Full payment received (date of receipt of payment) Request granted | 01.09.2023 | Decision despatched | Fees paid | Renewal fee | 27.05.2021 | Renewal fee patent year 03 | 27.05.2022 | Renewal fee patent year 04 | 30.05.2023 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.05.2024 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2015013671 (CYTOMX THERAPEUTICS INC [US], et al) [X] 50-69 * pages 192,177 * * page 172 * * sequences 270,276,282,304,77,78 *; | [XYI]WO2016014974 (CYTOMX THERAPEUTICS INC [US]) [X] 50-69 * sequences 372,548,568,10,34 * * sequences 570,550,12,36,741,510 * * sequences 454,462 * * paragraph [0591] * * pages 264-265 * [Y] 14-17 [I] 1-13,18-31,42-49; | [Y]WO2016118629 (CYTOMX THERAPEUTICS INC [US]) [Y] 14-17 * sequences 547,485,483 *; | [XP]WO2019075405 (CYTOMX THERAPEUTICS INC [US]) [XP] 1,50-59 * page 112 * * sequence 12 ** examples 1-22 * | by applicant | US3773919 | US4522811 | WO2009025846 | WO2010081173 | WO2010129609 | WO2015013671 | WO2016014974 | WO2016118629 | - LA ROCCA et al., British J. of Cancer, (20040000), vol. 90, no. 7, pages 1414 - 1421 | - SCHERAGA, Rev. Computational Chem., (19920000), pages 11173 - 142 | - BALDRICK P., "Pharmaceutical excipient development: the need for preclinical guidance", Regul. Toxicol Pharmacol., (20000000), vol. 32, no. 2, pages 210 - 8 | - WANG W., "Lyophilization and development of solid protein pharmaceuticals", Int. J. Pharm., (20000000), vol. 203, no. 1-2, doi:doi:10.1016/S0378-5173(00)00423-3, pages 1 - 60, XP002428586 DOI: http://dx.doi.org/10.1016/S0378-5173(00)00423-3 | - CHARMAN WN, "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts", J Pharm Sci., (20000000), vol. 89, no. 8, pages 967 - 78, XP008099512 | - POWELL et al., "Compendium of excipients for parenteral formulations", PDA J Pharm Sci Technol., (19980000), vol. 52, pages 238 - 311, XP009119027 | - ELISA, Theory and Practice: Methods in Molecular Biology, Human Press, (19950000), vol. 42 | - WANG W., "Lyophilization and development of solid protein pharmaceuticals", Int. J. Pharrn., (20000000), vol. 203, no. 1-2, doi:doi:10.1016/S0378-5173(00)00423-3, pages 1 - 60, XP002428586 DOI: http://dx.doi.org/10.1016/S0378-5173(00)00423-3 | - POWELL et al., "Compendium of excipients for parenteral formulations", PDA J Pharm Sci Technol., (19980000), vol. 52, pages 238 - 3 11 | - Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, M. Dekker, (19910000), vol. 4 |